C

Cellipont Bioservices Tech Stack

Cell therapy CDMO with GMP manufacturing and analytical development

Biotechnology Research The Woodlands, Texas 201–500 employees Privately Held

Cellipont operates a contract development and manufacturing organization (CDMO) for cell therapies, spanning bench-to-bedside process development and GMP-compliant batch production. Their tech stack is firmly Windows/Active Directory enterprise infrastructure with specialized biotech tools (JMP, FlowJo, FMEA) — typical for regulated manufacturing environments. Current hiring acceleration is concentrated in research and engineering roles, with active projects clustered around automation of analytical workflows and CAR-T scale-up, suggesting internal pressure to reduce manual testing bottlenecks and move methods toward higher throughput.

Tech Stack 14 technologies

Core StackWindows Server Active Directory Hyper-V Microsoft Exchange DNS DHCP Microsoft 365 Entra Teams SharePoint JMP FlowJo FMEA JD Edwards

What Cellipont Bioservices Is Building

◆Challenges

Automation of analytical methods
Filling technical gaps
High-throughput sample testing
Implementing new analytical technologies
Troubleshooting complex network issues
Ensuring server reliability
Optimizing system performance
Scale-up challenges
Technology transfer
Material discrepancies

▲Active Projects

Development of automated qc methods for high-throughput sample testing
Automation of analytical methods
Developing and validating analytical methods for cell therapy manufacturing
Transferring cell therapy methods
Cell therapy process optimization
Scale-up for car-t
Technology transfer for mscs
Documentation for new laboratory equipment
Technical transfer and qualification of processes and analytics
Process development and gmp manufacturing projects

Hiring Activity

Accelerating9 roles · 6 in 30d

Department

Research

3

Engineering

2

Manufacturing

2

Ops

1

Process

1

Seniority

Senior

4

Mid

3

Junior

2

Company intelligence

Find more companies like Cellipont Bioservices by tech stack, pain points and active projects

Get started free

About Cellipont Bioservices

Cellipont Bioservices manufactures cell therapies for pharma and biotech clients pursuing commercial development. The company operates GMP-compliant facilities and brings deep process expertise across CAR-T, NK cell, dendritic cell, and mesenchymal stem cell (MSC) platforms. Internally, they maintain 18,000+ tissue samples and 900+ primary cell cultures to support client development pipelines. Leadership has decades of experience in advanced therapy manufacturing at scale, positioning the organization as both a technical service provider and a compliance-ready partner for clients navigating FDA pathways to commercial approval.

HeadquartersThe Woodlands, Texas

Company Size201–500 employees

Hiring MarketsUnited States

Frequently Asked Questions

What cell therapy platforms does Cellipont manufacture?

Cellipont has extensive GMP experience in CAR-T, NK cells (iNK), dendritic cells, mesenchymal stem cells (MSCs), and other novel cell therapy modalities. They maintain 18,000+ tissue samples and 900+ primary cell cultures to support development and manufacturing across these platforms.

What is Cellipont's current focus in process development?

Current projects center on automation of analytical methods, high-throughput QC testing, CAR-T scale-up, technology transfer for MSCs, and process optimization. Key pain points include automation gaps in analytical workflows and scale-up challenges.